- Home
- TLSI vs PZC Comparison
TLSI vs PZC Comparison
Compare TLSI & PZC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- PZC
- Stock Information
- Founded
- TLSI 2010
- PZC 2002
- Country
- TLSI United States
- PZC United States
- Employees
- TLSI N/A
- PZC N/A
- Industry
- TLSI Medical Specialities
- PZC Investment Managers
- Sector
- TLSI Health Care
- PZC Finance
- Exchange
- TLSI Nasdaq
- PZC Nasdaq
- Market Cap
- TLSI 124.9M
- PZC 151.8M
- IPO Year
- TLSI N/A
- PZC N/A
- Fundamental
- Price
- TLSI $4.69
- PZC $6.62
- Analyst Decision
- TLSI Strong Buy
- PZC
- Analyst Count
- TLSI 6
- PZC 0
- Target Price
- TLSI $11.75
- PZC N/A
- AVG Volume (30 Days)
- TLSI 36.4K
- PZC 48.2K
- Earning Date
- TLSI 11-14-2024
- PZC 01-01-0001
- Dividend Yield
- TLSI N/A
- PZC 4.68%
- EPS Growth
- TLSI N/A
- PZC N/A
- EPS
- TLSI N/A
- PZC N/A
- Revenue
- TLSI $26,891,000.00
- PZC N/A
- Revenue This Year
- TLSI $60.96
- PZC N/A
- Revenue Next Year
- TLSI $53.65
- PZC N/A
- P/E Ratio
- TLSI N/A
- PZC N/A
- Revenue Growth
- TLSI 67.90
- PZC N/A
- 52 Week Low
- TLSI $3.50
- PZC $6.30
- 52 Week High
- TLSI $10.42
- PZC $8.20
- Technical
- Relative Strength Index (RSI)
- TLSI 51.68
- PZC 28.72
- Support Level
- TLSI $4.72
- PZC $6.83
- Resistance Level
- TLSI $5.32
- PZC $7.01
- Average True Range (ATR)
- TLSI 0.31
- PZC 0.11
- MACD
- TLSI 0.01
- PZC -0.01
- Stochastic Oscillator
- TLSI 47.52
- PZC 4.88
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About PZC PIMCO California Municipal Income Fund III of Beneficial Interest
PIMCO CA Muni Income Fund III operates as a closed-end management investment company. The investment objective of the fund is to seek to provide current income exempt from federal and California income tax. Its portfolio of investments includes investment in different sectors such as education, healthcare, industrial and others.